Merck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents ...

Omega Hospital, Guntur, a leading comprehensive cancer center in Andhra Pradesh, marked World Cancer Day 2025 under the theme ...

Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug ... % in the past year compared with a decline of 3.9% for the industry. Merck MRK stock has declined ...

Dr Nur Adila Mokhtar, Consultant Clinical Oncologist at OncoCare Cancer Centre Malaysia, shares, “The HPV vaccine is ...

GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1.

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue, but it still posted a strong ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck (MRK) anticipates full-year 2025 sales to be between $64.1B-$65.6B, including a negative impact of foreign exchange of approximately 2% ...

Kennedy Jr., President Trump’s nominee to run the Department of Health and Human Services, is giving away the fees that he could earn from litigation over Merck’s HPV vaccine Gardasil — to ...

"The approval of GARDASIL for use in males 9-26 years old in China is a significant step forward in advancing public health," said Joseph Romanelli, president, Human Health International ...